These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 1778336)

  • 1. The molecular engineering of pertussis toxoid.
    Burnette WN; Mar VL; Bartley TD; Kaslow HR; Cieplak W; Keith JM; Sato H; Burns DL; Arciniega JL; Shahin RD
    Dev Biol Stand; 1991; 73():75-8. PubMed ID: 1778336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering bacterial toxin for the development of new vaccine against pertussis.
    Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R
    Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction and characterization of genetically inactivated pertussis toxin.
    Brown DR; Keith JM; Sato H; Sato Y
    Dev Biol Stand; 1991; 73():63-73. PubMed ID: 1778335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acellular pertussis vaccine composed of genetically inactivated pertussis toxin.
    Peppoloni S; Pizza M; De Magistris MT; Bartoloni A; Rappuoli R
    Physiol Chem Phys Med NMR; 1995; 27(4):355-61. PubMed ID: 8768791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rise in pertussis cases urges replacement of chemically-inactivated with genetically-inactivated toxoid for DTP.
    Robbins JB; Schneerson R; Keith JM; Shiloach J; Miller M; Trollors B
    Vaccine; 2007 Apr; 25(15):2811-6. PubMed ID: 17291636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection.
    Heininger U; Stehr K; Christenson P; Cherry JD
    Clin Infect Dis; 1999 Mar; 28(3):602-4. PubMed ID: 10194085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Acellular pertussis vaccine].
    Wiedermann G; Ambrosch F; Vanura H
    Wien Med Wochenschr; 1991; 141(12):270-2. PubMed ID: 1949820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of routine vaccination with a pertussis toxoid vaccine in Denmark.
    Hviid A; Stellfeld M; Andersen PH; Wohlfahrt J; Melbye M
    Vaccine; 2004 Sep; 22(27-28):3530-4. PubMed ID: 15315832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pertussis vaccines: present status.
    Christodoulides M
    Adv Biotechnol Processes; 1990; 13():169-99. PubMed ID: 2185783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of safer pertussis DNA vaccine expressing non-toxic C180 polypeptide of pertussis toxin S1 subunit.
    Kamachi K; Arakawa Y
    Vaccine; 2007 Jan; 25(6):1000-6. PubMed ID: 17050047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cellular and acellular anti-pertussis vaccines].
    Locht C
    Ann Pharm Fr; 2001 May; 59(3):198-205. PubMed ID: 11427821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine in Japan.
    Sato H; Sato Y
    Clin Infect Dis; 1999 Jun; 28 Suppl 2():S124-30. PubMed ID: 10447030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acellular pertussis vaccines: a turning point in infant and adolescent vaccination.
    Rappuoli R
    Infect Agents Dis; 1996 Jan; 5(1):21-8. PubMed ID: 8789596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adolescent and adult pertussis: disease burden and prevention.
    Edwards K; Freeman DM
    Curr Opin Pediatr; 2006 Feb; 18(1):77-80. PubMed ID: 16470167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of humoral immunity in response to immunization with recombinant Mycobacterium bovis BCG expressing the S1 subunit of Bordetella pertussis toxin.
    Medeiros MA; Armôa GR; Dellagostin OA; McIntosh D
    Can J Microbiol; 2005 Dec; 51(12):1015-20. PubMed ID: 16462859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse reactions of a pertussis toxoid vaccine in a double-blind placebo-controlled trial.
    Taranger J; Trollfors B; Knutsson N
    Dev Biol Stand; 1997; 89():109-12. PubMed ID: 9272340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indications for acellular pertussis vaccines in adults: the case for selective, rather than universal, recommendations.
    Gardner P
    Clin Infect Dis; 1999 Jun; 28 Suppl 2():S131-5. PubMed ID: 10447031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prevention of pertussis and high expectations concerning vaccines].
    Wysocki J
    Przegl Epidemiol; 2004; 58 Suppl 1():39-43. PubMed ID: 15807156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified intra-cerebral challenge assay for acellular pertussis vaccines: comparisons among whole cell and acellular vaccines.
    Gaines-Das R; Horiuchi Y; Zhang SM; Newland P; Kim Y; Corbel M; Xing D
    Vaccine; 2009 Nov; 27(49):6824-32. PubMed ID: 19765397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.